Trajectories of Depressive Individual Symptoms over Time during Transcranial Photobiomodulation

Author:

Urata Minoru1,Cassano Paolo23ORCID,Norton Richard4,Sylvester Katelyn M.2,Watanabe Koichiro1,Iosifescu Dan V.56,Sakurai Hitoshi1ORCID

Affiliation:

1. Department of Neuropsychiatry, Faculty of Medicine, Kyorin University, Tokyo 181-8611, Japan

2. Division of Neuropsychiatry and Neuromodulation, Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02129, USA

3. Department of Psychiatry, Harvard Medical School, Boston, MA 02215, USA

4. Department of Psychological Sciences, University of Vermont, Burlington, VT 05405, USA

5. Clinical Research Division, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA

6. Department of Psychiatry, New York University School of Medicine, New York, NY 10016, USA

Abstract

Transcranial photobiomodulation (t-PBM) is an innovative, non-invasive treatment for depression. This study aimed to investigate the changes in individual depressive symptoms during t-PBM treatment and identify the symptoms that improved in those who responded to treatment. The research analyzed data from two trials, the Evaluation of Light-emitting diodes Therapeutic Effect in Depression-2 and -3, focusing on patients with major depressive disorder. The patients received t-PBM treatment on the F3 and F4 regions of the scalp over eight weeks, with symptoms assessed weekly using the Quick Inventory for Depression Symptomatology (QIDS). A response was defined as a 50% or greater reduction in the QIDS score at eight weeks from baseline. Out of the 21 patients analyzed, 4 responded at eight weeks. Neurovegetative symptoms, including sleep disturbances and change in appetite, improved in ≥50% of the patients who had these symptoms at baseline. However, core depressive symptoms, including a depressed mood and lack of energy, persisted in about 80–90% of the patients. The responders showed a more than 75% improvement in these core depressive symptoms. These findings suggest that t-PBM treatment may uniquely alleviate certain neurovegetative symptoms in depression, and the improvement in core depressive symptoms might be linked to a clinical response to this treatment.

Funder

Harvard Psychiatry Department

Brain and Behavior Research Foundation

Photomedex, Inc.

Litecure LLC

Publisher

MDPI AG

Subject

Radiology, Nuclear Medicine and imaging,Instrumentation,Atomic and Molecular Physics, and Optics

Reference36 articles.

1. Sakurai, H., Noma, H., Watanabe, K., Uchida, H., and Furukawa, T. (World Psychiatry, 2023). Cumulative Remission Rate after Sequential Treatments in Depression: Reappraisal of the STAR*D Trial Data, World Psychiatry, in press.

2. Drop-out Rates in Placebo-Controlled Trials of Antidepressant Drugs: A Systematic Review and Meta-Analysis Based on Clinical Study Reports;Sharma;Int. J. Risk Saf. Med.,2019

3. Variables Influencing Antidepressant Medication Adherence for Treating Outpatients with Depressive Disorders;Lee;J. Affect. Disord.,2010

4. Evidence of Cost-Effective Treatments for Depression: A Systematic Review;Barrett;J. Affect. Disord.,2005

5. Psychotherapy for Chronic Major Depression and Dysthymia: A Meta-Analysis;Cuijpers;Clin. Psychol. Rev.,2010

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3